STERIS reports fiscal 2025 adjusted EPS $9.22, revenue $5.5B; guides FY2026 EPS $9.90-$10.15

STERIS plc

2025-FY EPS reported $6.20 vs consensus $2.56 ▲ beat (+142.4%)

Full-year revenue from continuing ops +6% to $5.5B; constant currency organic growth 6%.
Adjusted diluted EPS $9.22 vs $8.20 prior year; as-reported EPS $6.16.
Q4 adjusted EPS $2.74 vs $2.41; revenue $1.5B (+4% as reported, +6% constant currency organic).
Healthcare revenue +5% (service +13%); AST +9% constant currency organic; Life Sciences flat organic.
FY2026 guidance: revenue +6-7%, adjusted EPS $9.90-$10.15; tariffs to reduce pre-tax profit ~$30M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.